Stockreport

POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-a Targeted Clinical Program [TheStreet.com]

POINT Biopharma Global Inc.  (PNT) 
PDF A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004's Phase 1 therapeutic trial using 68 Ga-PNT6555 for imaging and 177 Lu-PNT [Read more]